CN Bio appoints Lydia Seymour as VP People and Culture to further strengthen leadership team
June 27, 2024 – Biotechnology, Other, Pharmaceutical – CN Bio, appointments
Key appointment to support continued UK and US team expansion
27 June 2024 — Cambridge, UK — CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced the appointment of Lydia Seymour as vice president of People and Culture. In this role, Lydia will work alongside the company’s management team, providing guidance and support across recruitment and employee wellbeing, in addition to ensuring the implementation of robust professional development plans for CN Bio’s growing global team, and driving new initiatives to enhance workplace culture.
Lydia’s appointment follows several crucial senior hires made over the last year across both the UK and US in response to an ongoing surge in demand for new alternative methodologies (NAMs) such as the company’s PhysioMimix Organ-on-a-chip (OOC) range of microphysiological systems (MPS). Working with CEO Dr Paul Brooks, and the company’s leadership team, Lydia will be responsible for leading internal initiatives to foster collaborations and a supportive workplace culture, ensuring all necessary recruitment and development systems are embedded as the company continues to execute its global expansion strategy following the $21m first close of its Series B investment round in April 2024.
Lydia is a seasoned professional in HR and people management within the life science industry. Throughout her career, she has supported commercial, R&D and corporate teams globally, particularly specialising in the US and APAC markets. Lydia has held senior leadership positions at companies including Abcam, TTP Labtech and Fluidigm Corporation, where she successfully built high-performing people functions and led the design and implementation of development programmes, reward and talent management strategies. Most recently, Lydia was VP of Human Resources at Evonetix, during which time she oversaw the creation of the people systems and processes required to support the company’s growing team.
Dr Paul Brooks, CEO, CN Bio, commented: “We are extremely proud here at CN Bio to have built such a credible and professional team, who are helping to realise the full potential of Organ-on-a-chip technology to revolutionise drug discovery and development.” He continued: “At such a pivotal time in CN Bio’s development, Lydia’s expertise in overseeing thorough strategies to ensure effective recruitment and training, as well as fostering inclusive and supportive company culture will be crucial as our team continues to expand globally and underscores our commitment to investing in people as the foundation of our business growth and innovation.”
Lydia Seymour, vice president of People and Culture, CN Bio, said: “CN Bio’s innovative PhysioMimix OOC range of MPS hold great promise to transform how we approach drug discovery, enabling us to bring more effective therapies to market, faster. I look forward to harnessing my expertise in people management, working alongside Paul and the team to implement effective strategies that empower our talented team members to continue to innovate, and prepare the company for global expansion so that we can continue to meet the needs of our customers.”
About CN Bio
CN Bio is on a mission to accelerate drug discovery. As a leading Organ-on-chip (OOC) company, the team is transforming how human-specific efficacy and safety data are generated. CN Bio’s human organ models deepen the understanding of disease mechanisms, help uncover new drug targets and enable effective therapeutics to be developed safely. Throughout the discovery and development process, the company’s portfolio of products and services help save time and reduce costs. Based in Cambridge, UK, CN Bio brings over a decade of experience and know-how to engineering single and multi-organ microphysiological systems (MPS). As a result, the company’s ground-breaking benchtop PhysioMimix OOC range can accurately mimic human physiology in the laboratory. Using advanced, predictive in vitro human organ models, these systems enable the development of novel therapeutics with increased efficiency, whilst relieving the dependence on animal models. These models also offer valuable insights into how drugs will perform in patients, greatly reducing risks in the clinic. The power of PhysioMimix technology has been recognised by the US FDA, resulting in the first co- publication between a drug regulator and an MPS provider and has been harnessed by 13 of the leading pharmaceutical companies. In 2023, CN Bio helped deliver a regulatory world first, when the company supported Inipharm’s INI-822 successful filing to initiate clinical testing for the treatment of metabolic liver disease treatment. To find out more about CN Bio and how the company is pioneering faster, more accurate drug discovery, please visit: cn-bio.com
